- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US since May 2023.
- Why 4/10
- XACDURO was approved by the FDA on May 23, 2023, and is now a marketed, commercial-stage product with no pending regulatory decision or pivotal readout scheduled in the next 12 months. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
XACDURO is already approved and commercializing, so there is no single binary catalyst ahead. Watch quarterly IST product sales growth (Innoviva guided to at least $150M in total IST US net product sales for 2026) and any updates on the Dr. Reddy's international licensing deal. The stock trades near its 52-week low with a mean analyst price target of $35, implying significant upside if the commercial ramp continues, but the Q3 net loss of $73.9M from investment fair-value changes introduces headline risk.
Price Chart
Executive Summary
XACDURO (sulbactam/durlobactam) is an FDA-approved intravenous antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Approved in May 2023, it is the first and only pathogen-targeted therapy for this difficult-to-treat superbug. Developed by Entasis Therapeutics (now part of Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., NASDAQ: INVA), XACDURO generated $33.4 million in US net sales in FY2025 and $16.1 million in Q3 2026, with the broader IST platform on track for at least $150 million in full-year 2026 US product sales. A June 2026 licensing deal with Dr. Reddy's expands international reach. XACDURO is a commercial-stage product with no pending regulatory binary, making it a steady but not explosive contributor to Innoviva's diversified revenue base, which also includes a large GSK royalty stream and other critical-care products.
How It Works
XACDURO is a co-packaged intravenous antibiotic that combines two drugs: sulbactam (which kills Acinetobacter bacteria by blocking cell-wall construction) and durlobactam (which protects sulbactam from being broken down by bacterial resistance enzymes). It is designed specifically to treat hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii, a notoriously hard-to-treat "superbug" that is a growing problem in hospitals.
Trial Status
XACDURO was approved by the FDA on May 23, 2023, based on the Phase 3 ATTACK trial, which demonstrated non-inferiority to colistin on 28-day all-cause mortality with higher clinical cure rates in patients with serious Acinetobacter infections, including carbapenem-resistant strains.
The Two-Sided Case
Upcoming Catalysts
- Quarterly IST product sales reports and progress toward the 2026 guidance of at least $150M in US net product sales
- Potential updates on Dr. Reddy's international commercialization milestones for XACDURO in licensed territories
- Possible label expansion or pediatric study updates (though none currently scheduled)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Innoviva, Inc. 8-K INVA ·Originating report